EP Patent

EP3250198A1 — Multiple sclerosis treatment regimen using dimethyl fumarate

Assigned to Biogen MA Inc · Expires 2017-12-06 · 8y expired

What this patent protects

Provided herein are methods of treating multiple sclerosis with dimethyl fumarate using an up-titration regimen. The methods provided herein are to reduce dimethyl fumarate-related gastro-intestinal adverse events in multiple sclerosis patients.

USPTO Abstract

Provided herein are methods of treating multiple sclerosis with dimethyl fumarate using an up-titration regimen. The methods provided herein are to reduce dimethyl fumarate-related gastro-intestinal adverse events in multiple sclerosis patients.

Drugs covered by this patent

Patent Metadata

Patent number
EP3250198A1
Jurisdiction
EP
Classification
—
Expires
2017-12-06
Drug substance claim
No
Drug product claim
No
Assignee
Biogen MA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.